drugset / Trial / NCT02968212
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
Phase 2
Active not recruiting
102 enrolled
Oregon Health and Science University
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Jewish Health · collabTemple University · collabThe University of Texas Health Science Center at Tyler · collabUniversity of Chicago · collabUniversity of South Florida · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD
Timeline
- Start
- 2017-04-11
- Primary completion
- 2025-08-29
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofazimine | Small molecule | 100 mg | — |